John Kuruvilla, MD, FRCPC, Princess Margaret Cancer Center, Toronto, Canada, outlines the results of a retrospective study comparing lisocabtagene maraleucel (liso-cel) and tisagenlecleucel (tisa-cel) in patients with diffuse large B-cell lymphoma (DLBCL) in the third-line setting. Whilst both CAR-T therapies had a favorable safety profile, liso-cel appeared to be more effective. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.